 we report on our third quarter 2019 financial results and discuss our plans for commercialization of cytisinicline. 
 we also provide an update on our ongoing discussions with potential partners for commercialization of cytisinicline, and also on preparations for the upcoming phase three clinical trials.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in    # 1#2#3#4#1 * # 2 *, # 3 ( # 4 ) # 1#2#3#4#5#6#7#8#9#10    # 1#2#3@xmath0 # 1#2#3@xmath1 # 1#2#3@xmath2 # 1#2#3@xmath3 # 1#2#3@xmath4 # 1#2#3@xmath5 # 1#2#3@xmath6 # 1#2#3@xmath7 # 1#2#3@xmath8 # 1#2#3@xmath9 # 1#2#3@xmath10 # 1#2#3@xmath11 # 1#2#3@xmath12 # 1#2#3@xmath13 # 1#2#3@xmath14 # 1#2#3@xmath15 # 1#2#3@xmath16 # 1#2#3@xmath17 # 1#2#3@xmath18 # 1#2#3@xmath19 # 1#2#3@xmath20 # 1#2#3@xmath21 # 1#2#3@xmath22 # 1#2#3@xmath23 # 1#2#3@xmath24 # 1#2#3@xmath25 # 1#2#3@xmath26 # 1#2#3@xmath27 # 1#2#3@xmath28 # 1#2#3@xmath29 # 1#2#3@xmath40 # 1#2#3@xmath51 # 1#2#3@xmath60 # 1#2#3@xmath61 # 1#2#3@xmath62 # 1#2#3@xmath70 # 1#2#3@xmath71 # 1#2#3@xmath72 # 1#2#3@xmath73     #